These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11249571)

  • 41. Synercid Aventis.
    Pavan B
    Curr Opin Investig Drugs; 2000 Oct; 1(2):173-80. PubMed ID: 11249570
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Linezolid for the treatment of infections caused by Gram-positive pathogens in China.
    Lin DF; Zhang YY; Wu JF; Wang F; Zheng JC; Miao JZ; Zheng LY; Sheng RY; Zhou X; Shen HH; Ijzerman MM; Croos-Dabrera RV; Sheng W
    Int J Antimicrob Agents; 2008 Sep; 32(3):241-9. PubMed ID: 18635341
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oxazolidinones: activity, mode of action, and mechanism of resistance.
    Bozdogan B; Appelbaum PC
    Int J Antimicrob Agents; 2004 Feb; 23(2):113-9. PubMed ID: 15013035
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Conformational constraint in oxazolidinone antibacterials. Synthesis and structure-activity studies of (azabicyclo[3.1.0]hexylphenyl)oxazolidinones.
    Renslo AR; Jaishankar P; Venkatachalam R; Hackbarth C; Lopez S; Patel DV; Gordeev MF
    J Med Chem; 2005 Jul; 48(15):5009-24. PubMed ID: 16033280
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan.
    Kohno S; Yamaguchi K; Aikawa N; Sumiyama Y; Odagiri S; Aoki N; Niki Y; Watanabe S; Furue M; Ito T; Croos-Dabrera R; Tack KJ
    J Antimicrob Chemother; 2007 Dec; 60(6):1361-9. PubMed ID: 17913720
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Experience with linezolid therapy in children with osteoarticular infections.
    Chen CJ; Chiu CH; Lin TY; Lee ZL; Yang WE; Huang YC
    Pediatr Infect Dis J; 2007 Nov; 26(11):985-8. PubMed ID: 17984803
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Linezolid: a review of its use in the management of serious gram-positive infections.
    Perry CM; Jarvis B
    Drugs; 2001; 61(4):525-51. PubMed ID: 11324682
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The first clinical experiences in Hungary with a new effective antibiotic (linezolid) effective against Gram-positive infections].
    Pulay I; Konkoly TM; Zsirka KA; Csapó Z; Flautner L; Tihanyi T
    Orv Hetil; 2003 Jan; 144(1):29-33. PubMed ID: 12635350
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Linezolid resistance in a clinical isolate of Staphylococcus aureus.
    Tsiodras S; Gold HS; Sakoulas G; Eliopoulos GM; Wennersten C; Venkataraman L; Moellering RC; Ferraro MJ
    Lancet; 2001 Jul; 358(9277):207-8. PubMed ID: 11476839
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.
    Jauregui LE; Babazadeh S; Seltzer E; Goldberg L; Krievins D; Frederick M; Krause D; Satilovs I; Endzinas Z; Breaux J; O'Riordan W
    Clin Infect Dis; 2005 Nov; 41(10):1407-15. PubMed ID: 16231250
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Benefit-risk assessment of linezolid for serious gram-positive bacterial infections.
    Falagas ME; Vardakas KZ
    Drug Saf; 2008; 31(9):753-68. PubMed ID: 18707190
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Linezolid: pharmacokinetic characteristics and clinical studies.
    Bouza E; Muñoz P
    Clin Microbiol Infect; 2001; 7 Suppl 4():75-82. PubMed ID: 11688537
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Linezolid--a review of the first oxazolidinone.
    Norrby R
    Expert Opin Pharmacother; 2001 Feb; 2(2):293-302. PubMed ID: 11336587
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Linezolid: a review of its properties, function, and use in critical care.
    Hashemian SMR; Farhadi T; Ganjparvar M
    Drug Des Devel Ther; 2018; 12():1759-1767. PubMed ID: 29950810
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oxazolidinone antibiotics.
    Diekema DJ; Jones RN
    Lancet; 2001 Dec; 358(9297):1975-82. PubMed ID: 11747939
    [TBL] [Abstract][Full Text] [Related]  

  • 56. AZD-2563 AstraZeneca.
    Johnson AP
    Curr Opin Investig Drugs; 2002 Jun; 3(6):848-52. PubMed ID: 12137402
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center.
    Kloss P; Xiong L; Shinabarger DL; Mankin AS
    J Mol Biol; 1999 Nov; 294(1):93-101. PubMed ID: 10556031
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Linezolid - the first oxazolidinone in the treatment of nosocomial MRSA pneumonia.
    Burkhardt O; Pletz MW; Mertgen CP; Welte T
    Recent Pat Antiinfect Drug Discov; 2007 Jun; 2(2):123-30. PubMed ID: 18221168
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differences in clinical outcomes in patients with vancomycin-resistant enterococci according to linezolid susceptibility.
    Scheetz MH; Knechtel SA; Postelnick MJ; Malczynski M; Qi C
    Pharmacotherapy; 2010 Dec; 30(12):1221-8. PubMed ID: 21114389
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Antimicrobial and clinical effect of linezolid (ZYVOX), new class of synthetic antibacterial drug].
    Irinoda K; Nomura S; Hashimoto M
    Nihon Yakurigaku Zasshi; 2002 Oct; 120(4):245-52. PubMed ID: 12425150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.